Purpose: In the MONALEESA-3 Phase III trial of patients with hormone receptor–positive human epidermal growth factor receptor–negative advanced breast cancer, ribociclib plus fulvestrant significantly improved progression-free survival (PFS) and overall survival (OS). Here, we present patient-reported outcomes from the trial, including health-related quality of life (HRQOL). Methods: Patients were randomized (2:1) to receive ribociclib plus fulvestrant or placebo plus fulvestrant. Time to definitive 10% deterioration (TTD) from baseline in HRQOL (global health status [GHS] from the EORTC QLQ-C30 questionnaire) and pain (BPI-SF questionnaire) were assessed using Kaplan-Meier estimates; a stratified Cox regression model was used to estimate t...
Background: This analysis evaluated patient-reported outcomes (PROs) to assess health-related qualit...
Evaluate patient-reported outcomes (PROs) for postmenopausal women with hormone receptor-positive (H...
Background: The phase III MONALEESA-3 trial included first- (1L) and second-line (2L) patients and d...
Purpose: In the MONALEESA-3 Phase III trial of patients with hormone receptor–positive human epiderm...
peer reviewedPURPOSE: In the MONALEESA-3 Phase III trial of patients with hormone receptor-positive ...
© 2021 Elsevier Inc.Background: MONALEESA-3 demonstrated an overall survival (OS) benefit for riboci...
Y Background: Ribociclib plus fulvestrant demonstrated significant progression-free survival (PFS) a...
peer reviewedBACKGROUND: In an earlier analysis of this phase 3 trial, ribociclib plus fulvestrant s...
BACKGROUND In an earlier analysis of this phase 3 trial, ribociclib plus fulvestrant showed a greate...
BACKGROUND: In the phase III MONARCH 2 study (NCT02107703), abemaciclib plus fulvestrant significant...
Purpose This phase III study evaluated ribociclib plus fulvestrant in patients with hormone receptor...
Purpose This phase III study evaluated ribociclib plus fulvestrant in patients with hormone receptor...
BACKGROUND In an earlier analysis of this phase 3 trial, ribociclib plus fulvestrant showed a greate...
Ribociclib plus fulvestrant demonstrated significant progression-free survival (PFS) and overall sur...
BACKGROUND: In the phase III MONARCH 2 study (NCT02107703), abemaciclib plus fulvestrant significant...
Background: This analysis evaluated patient-reported outcomes (PROs) to assess health-related qualit...
Evaluate patient-reported outcomes (PROs) for postmenopausal women with hormone receptor-positive (H...
Background: The phase III MONALEESA-3 trial included first- (1L) and second-line (2L) patients and d...
Purpose: In the MONALEESA-3 Phase III trial of patients with hormone receptor–positive human epiderm...
peer reviewedPURPOSE: In the MONALEESA-3 Phase III trial of patients with hormone receptor-positive ...
© 2021 Elsevier Inc.Background: MONALEESA-3 demonstrated an overall survival (OS) benefit for riboci...
Y Background: Ribociclib plus fulvestrant demonstrated significant progression-free survival (PFS) a...
peer reviewedBACKGROUND: In an earlier analysis of this phase 3 trial, ribociclib plus fulvestrant s...
BACKGROUND In an earlier analysis of this phase 3 trial, ribociclib plus fulvestrant showed a greate...
BACKGROUND: In the phase III MONARCH 2 study (NCT02107703), abemaciclib plus fulvestrant significant...
Purpose This phase III study evaluated ribociclib plus fulvestrant in patients with hormone receptor...
Purpose This phase III study evaluated ribociclib plus fulvestrant in patients with hormone receptor...
BACKGROUND In an earlier analysis of this phase 3 trial, ribociclib plus fulvestrant showed a greate...
Ribociclib plus fulvestrant demonstrated significant progression-free survival (PFS) and overall sur...
BACKGROUND: In the phase III MONARCH 2 study (NCT02107703), abemaciclib plus fulvestrant significant...
Background: This analysis evaluated patient-reported outcomes (PROs) to assess health-related qualit...
Evaluate patient-reported outcomes (PROs) for postmenopausal women with hormone receptor-positive (H...
Background: The phase III MONALEESA-3 trial included first- (1L) and second-line (2L) patients and d...